利拉格卢提德通过YAP-TAZ通路改善衰老和改善糖尿病缩症
Qian Xu1, Xuan Qiu2, Hailing Di3
1Department of Emergency, Hebei Medical University Third Hospital, Shijiazhuang, Hebei, China.
Journal of diabetes and its complications
|February 23, 2025
概括
类似葡萄糖类-1受体激动剂 (GLP-1RAs),如利拉格卢提德,可以对抗糖尿病. 利拉格卢提德治疗改善了糖尿病大鼠的肌肉质量和功能,通过调节YAP/TAZ通路,为肌肉退化治疗提供了潜在的可能性.
科学领域:
- 内分泌学和新陈代谢学
- 肌肉生物学 肌肉生物学
- 衰老研究研究 衰老研究
背景情况:
- 葡萄糖样-1受体激动剂 (GLP-1RAs) 已知用于葡萄糖和体重管理.
- 新出现的证据表明GLP-1RAs也可能抵消肉症,这是一种以肌肉损失为特征的疾病.
- 糖尿病性肉症是一种与糖尿病有关的特定形式的肌肉退化,需要进一步研究治疗干预措施.
研究的目的:
- 为了研究利拉格卢提德在减轻糖尿病缩症方面的疗效.
- 阐明底层的分子机制,通过这种机制,利拉格卢提德会影响糖尿病的肌肉衰老和缩.
主要方法:
- 建立了一种2型糖尿病大鼠模型,并用liraglutide治疗.
- 肌肉质量,组织学和纤维类型在体内进行了评估.
- 在试验室中使用C2C12细胞核细胞来模拟高葡萄糖诱导的肌肉细胞衰老和缩.
- 西方涂抹和免疫光被用来分析衰老标志物和YAP/TAZ通路.
主要成果:
- 利拉格卢提德治疗显著改善了糖尿病大鼠的肌肉质量,长度和纤维组织.
- 实验室研究表明,利拉格卢提德可以减少高葡萄糖诱导的肌管衰老和缩.
- 利拉古类药物逆转了与糖尿病相关的YAP/TAZ/TEAD和Cyclin D1水平的下降以及P53和P21的增加.
结论:
- 高葡萄糖会加速肌肉细胞衰老和肉症.
- 利拉格卢提德通过调节YAP/TAZ信号通路,显示出对糖尿病皮症的保护作用.
- 这些发现凸显了利拉格卢的治疗潜力,用于糖尿病皮症的肌肉退化.
更多相关视频
10:39A Suppressor Screen for the Characterization of Genetic Links Regulating Chronological Lifespan in Saccharomyces cerevisiae
Published on: September 17, 2020
6.2K
07:16Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
19.6K
相关概念视频
Glucagon-like Receptor Agonists
291
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
291
Dipeptidyl Peptidase 4 Inhibitors
163
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
163
Oral Hypoglycemic Agents: Biguanides and Glitazones
158
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
158
Oral Hypoglycemic Agents: Glinides
131
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
131
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K
